Cocrystal Pharma Inc
For the period ended Jun 30, 2024. Filed Aug 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 14, 2024
COCP$1.03-6.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(in thousands)
| Six months ended June 30, | ||
|---|---|---|
| 2024 | 2023 | |
| Operating activities: | ||
| Net loss | $(9,299) | $(9,355) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization expense | 68 | 96 |
| Stock-based compensation | 305 | 470 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | 1,408 | 183 |
| Deposits | 17 | - |
| Tax credit receivable | (187) | (491) |
| Decrease in right of use assets | 178 | 108 |
| Accounts payable and accrued expenses | (619) | 445 |
| Operating lease liabilities | (73) | (115) |
| Net cash used in operating activities | (8,202) | (8,659) |
| Investing activities: | ||
| Purchases of property and equipment | (8) | (59) |
| Net cash used in investing activities | (8) | (59) |
| Financing activities: | ||
| Payments on finance lease liabilities | - | (7) |
| Proceeds from sale of common stock, net of transaction costs | - | 4,000 |
| Net cash used in financing activities | - | 3,993 |
| Net decrease in cash and restricted cash | (8,210) | (4,725) |
| Cash and restricted cash at beginning of period | 26,428 | 37,219 |
| Cash and restricted cash at end of period | $18,218 | $32,494 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.